Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5171827 | 0.94 | BCHE (0.45) | BCHEMEN1CYP1A2KMT2APOLB | |
| SCHEMBL22605688 | 0.93 | ADORA3 (0.55) | BCHEMEN1CYP1A2KMT2APOLB | |
| SCHEMBL21069295 | 0.89 | POLB (0.45) | BCHEMEN1CYP1A2KMT2APOLB | |
| SCHEMBL5244170 | 0.84 | ERCC1 (0.42) | BCHEADORA3ADORA1OPRM1OPRK1 | |
| SCHEMBL891295 | 0.83 | DYRK1A (0.49) | DRD2 | |
| SCHEMBL897551 | 0.83 | B3GNT2 (0.55) | BCHEHPGDALDH1A1DRD2IDO1 | |
| SCHEMBL891359 | 0.82 | KDM4E (0.47) | MEN1KMT2AHPGDALDH1A1MAPT | |
| SCHEMBL7058947 | 0.82 | MEN1 (0.56) | MEN1CYP1A2KMT2APOLBHPGD | |
| SCHEMBL23997380 | 0.81 | LMNA (0.55) | MEN1CYP1A2KMT2AHPGDALDH1A1 | |
| SCHEMBL30336597 | 0.81 | LMNA (0.55) | MEN1CYP1A2KMT2AHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | GENEROS BIOPHARMA LTD. (CN) | 2023-03-30 | — | — | US | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11530220-B2 | Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR | IDEAYA BIOSCIENCES, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-2268273-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7772266-B2 | treating or preventing benign prostatic hyperplasia, enlarged prostate, acute urinary retention with 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid (2-amino-2-phenyl-ethyl)-amide; agonists or antagonists of a transient receptor potential proteins; anticarcinogenic agent | DENDREON CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7741355-B2 | Small-molecule modulators of TRP-p8 activity | DENDREON CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-7544701-B2 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544701-B2 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544701-B2 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-06-09 | — | — | US | disclosed |
| WO-2009067410-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | DENDREON CORPORATION (US) | 2007-10-04 | — | — | US | disclosed |
| US-20050020575-A1 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | STAT5A, STAT5B, JAK2 | BCHE 4472/4885MEN1 1881/4885CYP1A2 3491/4885 |
| US-20070232603-A1 | Small-molecule modulators of TRP-P8 activity | TRPC4, TRPC3, TRPC1 | BCHE 4109/4885MEN1 2510/4885CYP1A2 4653/4885 |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | BCHE 2138/4885MEN1 4767/4885CYP1A2 55/4885 |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | BCHE 4109/4885MEN1 2510/4885CYP1A2 4653/4885 |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | BCHE 2138/4885MEN1 4767/4885CYP1A2 55/4885 |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | BCHE 2138/4885MEN1 4767/4885CYP1A2 55/4885 |
| US-11530220-B2 | Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR | AHR, ARNT, CYP1A1 | BCHE 3277/4885MEN1 4222/4885CYP1A2 14/4885 |
| US-20050020575-A1 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1B | BCHE 779/4885MEN1 2598/4885CYP1A2 773/4885 |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | BCHE 2138/4885MEN1 4767/4885CYP1A2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.